Literature DB >> 18318438

Activation of liver X receptor sensitizes mice to gallbladder cholesterol crystallization.

Hirdesh Uppal1, Yonggong Zhai, Archana Gangopadhyay, Shaheen Khadem, Songrong Ren, James A Moser, Wen Xie.   

Abstract

UNLABELLED: Gallstone disease is a hepatobiliary disorder due to biochemical imbalances in the gallbladder bile. In this report, we show that activation of nuclear receptor liver X receptor (LXR) sensitized mice to lithogenic diet-induced gallbladder cholesterol crystallization, which was associated with dysregulation of several hepatic transporters that efflux cholesterol, phospholipids, and bile salts. The combined effect of increased biliary concentrations of cholesterol and phospholipids and decreased biliary concentrations of bile salts in LXR-activated mice led to an increased cholesterol saturation index and the formation of cholesterol crystals. Interestingly, the lithogenic effect of LXR was completely abolished in the low-density lipoprotein receptor (Ldlr) null background or when the mice were treated with Ezetimibe, a cholesterol-lowering drug that blocks intestinal dietary cholesterol absorption. These results suggest that LDLR-mediated hepatic cholesterol uptake and intestinal cholesterol absorption play an essential role in LXR-promoted lithogenesis.
CONCLUSION: The current study has revealed a novel lithogenic role of LXR as well as a functional interplay between LXR and LDLR in gallbladder cholesterol crystallization and possibly cholesterol gallstone disease (CGD). We propose that LXR is a lithogenic factor and that the LXR transgenic mice may offer a convenient CGD model to develop therapeutic interventions for this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18318438     DOI: 10.1002/hep.22175

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  24 in total

1.  Liver X receptor β and peroxisome proliferator-activated receptor δ regulate cholesterol transport in murine cholangiocytes.

Authors:  Xuefeng Xia; Dongju Jung; Paul Webb; Aijun Zhang; Bin Zhang; Lifei Li; Stephen D Ayers; Chiara Gabbi; Yoshiyuki Ueno; Jan-Åke Gustafsson; Gianfranco Alpini; David D Moore; Gene D Lesage
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

Review 2.  Targets for current pharmacologic therapy in cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q H Wang; Helen H Wang; Leonilde Bonfrate; Piero Portincasa
Journal:  Gastroenterol Clin North Am       Date:  2010-06       Impact factor: 3.806

Review 3.  An update on the pathogenesis of cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q-H Wang; Piero Portincasa
Journal:  Curr Opin Gastroenterol       Date:  2018-03       Impact factor: 3.287

4.  Association of liver X receptors (LXRs) genetic variants to gallbladder cancer susceptibility.

Authors:  Kiran Lata Sharma; Sanjeev Misra; Ashok Kumar; Balraj Mittal
Journal:  Tumour Biol       Date:  2013-07-11

Review 5.  Recent Advances in the Critical Role of the Sterol Efflux Transporters ABCG5/G8 in Health and Disease.

Authors:  Helen H Wang; Min Liu; Piero Portincasa; David Q-H Wang
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  PXR prevents cholesterol gallstone disease by regulating biosynthesis and transport of bile salts.

Authors:  Jinhan He; Shigeru Nishida; Meishu Xu; Makoto Makishima; Wen Xie
Journal:  Gastroenterology       Date:  2011-02-24       Impact factor: 22.682

Review 7.  Mouse models of gallstone disease.

Authors:  Tony Y Wang; Piero Portincasa; Min Liu; Patrick Tso; David Q-H Wang
Journal:  Curr Opin Gastroenterol       Date:  2018-03       Impact factor: 3.287

8.  Activation of liver X receptor increases acetaminophen clearance and prevents its toxicity in mice.

Authors:  Simrat P S Saini; Bin Zhang; Yongdong Niu; Mengxi Jiang; Jie Gao; Yonggong Zhai; Jung Hoon Lee; Hirdesh Uppal; Hui Tian; Michael A Tortorici; Samuel M Poloyac; Wenxin Qin; Raman Venkataramanan; Wen Xie
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

9.  Hepatic insulin resistance directly promotes formation of cholesterol gallstones.

Authors:  Sudha B Biddinger; Joel T Haas; Bian B Yu; Olivier Bezy; Enxuan Jing; Wenwei Zhang; Terry G Unterman; Martin C Carey; C Ronald Kahn
Journal:  Nat Med       Date:  2008-06-29       Impact factor: 53.440

10.  Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters.

Authors:  Mark A Valasek; Joyce J Repa; Gang Quan; John M Dietschy; Stephen D Turley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-08-21       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.